Clincosm LogoSign in Get a demo

Molecular Modulation of the Growth Plate

Sponsor
Mayo Clinic (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT03501589
Collaborator
(none)
100
Enrollment
1
Location
125
Anticipated Duration (Months)
0.8
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The researchers are trying to identify molecular mechanisms that control growth plate mediated limb growth and identify agents that can be used to enhance or slow growth.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    100 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Prospective
    Official Title:
    Molecular Modulation of the Growth Plate
    Actual Study Start Date :
    Oct 31, 2013
    Anticipated Primary Completion Date :
    Oct 31, 2023
    Anticipated Study Completion Date :
    Apr 1, 2024

    Outcome Measures

    Primary Outcome Measures

    1. RNA expression [End of Study (1/2019]

      Measure RNA levels in growth plate tissue samples (ng/mL)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Skeletally immature children/adults undergoing surgical procedures where growth plate cartilage is removed as a normal part of their procedure; or patients undergoing surgical procedures where bone is removed as a normal part of their procedure.
    Exclusion Criteria:
    • Skeletally mature children/adults

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Mayo Clinic' Rochester Minnesota United States 55905

    Sponsors and Collaborators

    • Mayo Clinic

    Investigators

    • Principal Investigator: A. Noelle Larson, M.D., Mayo Clinic

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    A. Noelle Larson, Principal Investigator, Mayo Clinic
    ClinicalTrials.gov Identifier:
    NCT03501589
    Other Study ID Numbers:
    • 13-005403
    First Posted:
    Apr 18, 2018
    Last Update Posted:
    Mar 18, 2022
    Last Verified:
    Mar 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Salter-Harris Fractures

    Study Results

    No Results Posted as of Mar 18, 2022